The 2017 Prix Galien Canada laureates
The Prix Galien Canada - Research was awarded to Dr. Ernesto Schiffrin. Dr. Ernesto Schiffrin is one of Canada’s most outstanding clinician scientists whose bench to bedside insights into the mechanisms and therapy of hypertension have had a transformative effect on our understanding and management of cardiovascular disease.
Dr Jean Gray, president of the Jury and Dr Ernesto Schiffrin, vice-chair (research),
department of Medicine, McGill University
The Prix Galien Canada - Innovative Product was awarded to Pembrolizumab (Keytruda) - Merck Canada Inc. Keytruda is a highly selective humanized anti-programmed cell death receptor-1 (PD-1) antibody that restores T-cell mediated immune response against different types of cancer cells including advanced non-small cell lung carcinoma (NSLC).
Dr Jean Gray, president of the Jury, Augusto Villanueva, Business Unit Head, Oncology,
Merck Canada and Honorary Jury president Jacques Gagné